Tenelia M SR (metformin/teneligliptin) / Handok - LARVOL DELTA

An Efficacy and Safety Study of Remogliflozin in Obese Indian Type 2 Diabetes Mellitus Patients Who Were Inadequately Controlled on Insulin glargine plus other oral hypoglycemic agents. (PubMed, Curr Diabetes Rev) - "Results demonstrate that in uncontrolled T2DM patients remogliflozin 100 mg BD can successfully lay a foundation for prolonged good glycemic control. Early addition of remogliflozin with insulin glargine plus OHAs may be an alternative compare to intensive up titration of insulin daily dose in people with uncontrolled T2DM."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes. (PubMed, Diabetes Metab Syndr Obes) - "Our aim was to investigate the effects of add-on canagliflozin with glimepiride dose adjustment or glimepiride dose adjustment on pancreatic beta cell function in patients with type 2 diabetes mellitus and inadequate glycemic control despite stable triple therapy (metformin, teneligliptin, and glimepiride) plus diet/exercise therapy...As canagliflozin improved both glucose level and variability with relatively lower risk of hypoglycemia compared with glimepiride dose adjustment, adding canagliflozin to the triple therapy may be clinically beneficial. UMIN000030208/jRCTs051180036."

Clinical • Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design. (PubMed, Bioorg Chem) - No abstract available

Journal

Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes. (PubMed, Am J Med Sci) - "Teneligliptin reduced the plasma concentrations of 3 chemokines (DPP-4 substrates) that may be related to the occurrence of DPP4 inhibitor-associated BP (UMIN000012508)."

Clinical • Journal • Complement-mediated Rare Disorders • Dermatology • Dermatopathology • Diabetes • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

[VIRTUAL] Effects of teneligliptin on continuous glucose monitoring-derived time-in range and glycaemic variability in patients aged 65 years and older with type 2 diabetes (EASD 2020) - P4 | "Materials and In this randomized, double-blind, placebo-controlled trial, sixty-five subjects (HbA 1c 7.0-9.0%, fasting plasma glucose [FPG] < 270 mg/dL) who were treatment-naïve or had been treated with stable doses of metformin were randomized to receive either placebo or teneligliptin 20 mg once daily for 12 weeks... Teneligliptin (20 mg/day) effectively reduces HbA 1c and improves TIR and glucose variability without increasing TBR hypoglycemia. Therefore, it could be a good therapeutic choice in older patients with T2D. Clinical Trial Registration Number NCT03508323"

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Eff ectiveness of Teneligliptin as an Add-on in T2DM Patients not Controlled on Metformin and Glimepiride. (PubMed, J Assoc Physicians India) - No abstract available

Clinical • Journal • Type 2 Diabetes Mellitus

Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2). (PubMed, Diabetes Ther) - "Teneligliptin significantly improved glycaemic parameters in Indian patients with T2DM when prescribed either as monotherapy or as an add-on to one or more other commonly prescribed antihyperglycaemic agents."

Journal • Real-World Evidence • Retrospective data • Diabetes • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus

Joint pain in Type 2 diabetes mellitus patients taking DPP-4 inhibitors (IDF 2017) - "...They are approved as add on to metformin therapy...Others in use were Vildagliptin (21, 17%), Teneligliptin (9, 7.3%) and Linagliptin (2, 1.6%)...Keeping this in mind, we can avoid unnecessary analgesic use in patients who develop joint pain and may be labelled as Osteoarthritis, by discontinuing DPP4i and seeing for resolution of symptoms of pain. Further studies may help in identifying the magnitude of the problem and the pathways involved leading to arthralgias/arthritis."

Clinical • Diabetes

TETRIS: Tenelia Triple Combination Study (clinicaltrials.gov) - P3; N=201; Completed; Sponsor: Handok Pharmaceuticals Co., Ltd.; Recruiting ➔ Completed; Trial completion date: May 2017 ➔ Dec 2017; Trial primary completion date: Feb 2017 ➔ Oct 2017

Trial completion • Trial completion date • Trial primary completion date • Biosimilar • Diabetes

Development and Validation of a Stability Indicating RP-HPLC Method for Simultaneous Estimation of Teneligliptin and Metformin. (PubMed, Turk J Pharm Sci) - "This method was successfully validated for all the parameters and could detect the the correct amounts of active drug substance in formulations that are available in the market. This developed method in the present study could be successfully employed for the simultaneous estimation of teneligliptin and metformin in bulk and tablet dosage form."

Journal

Evaluation of the Safety and Efficacy of Teneligliptin at a Higher Dose in Indian Type 2 Diabetes Patients: A Retrospective Analysis. (PubMed, Cureus) - "This study aimed to evaluate the safety and efficacy of teneligliptin in Indian patients with type 2 DM inadequately controlled with diet, exercise, and a maximal dose of metformin treatment...Conclusion The current results demonstrated a high level of efficacy as an add-on therapy of teneligliptin at a high dose with inadequately controlled type 2 DM subjects in India. The study results also indicate the good tolerance of this drug with no critical adverse event in this study design."

Journal • Retrospective data

Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial. (PubMed, Diabetes Obes Metab) - P3; "Teneligliptin was non-inferior to sitagliptin in the context of triple therapy for T2DM and is an important option in this setting (NCT02567994)."

Clinical • Head-to-Head • Journal

Assessment of Teneligliptin efficacy in Indian T2DM patients among adult age groups in real world setting (IDF 2019) - "Teneligliptin significantly improved glycemic parameters when prescribed either as monotherapy or as an add-on to one or more other commonly prescribed antidiabetic drugs across age groups of <60 years age, 60 to <75 years & ≥ 75 years, in Indian T2DM patients."

Clinical • Real-World Evidence

Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Teneligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial. (PubMed, Diabetes Ther) - "A total of 200 patients with T2DM treated with metformin alone or without glucose-lowering agents will be enrolled if they have one or more of the metabolic risk factors, such as obesity, borderline high blood pressure, and dyslipidemia...University Hospital Medical Information Network Clinical Trial Registry number: UMIN000030343. Mitsubishi Tanabe Pharma Corporation."

Clinical • Journal

A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study. (PubMed, J Assoc Physicians India) - "We evaluated the efficacy and safety of teneligliptin versus sitagliptin as add-on to metformin and/or sulfonylureas in patients with type 2 diabetes mellitus (T2DM)...Teneligliptin provided similar glycemic control as compared to sitagliptin and reduced HbA1c, FBG and PPBG values significantly within 12 weeks of treatment. Both gliptins were found to be safe and well-tolerated in Indian patients with T2DM."

Clinical • Journal

Teneligliptin Significantly Reduces Liver Fat Content (LFC) and Delays Progression of NASH in Type 2 Diabetes Mellitus Patients (ADA 2019) - "...GROUP B(n=30): Metformin 1000mg Once a day... Result of our study revealed that Teneligliptin significantly reduce serum transaminases and liver fat content (LFC) and delay progression of NASH in type 2 diabetes mellitus patients."

Clinical

A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus. (PubMed, J Family Med Prim Care) - "There was no significant change in BMI levels between the groups. Compared to metformin plus teneligliptin, metformin plus glimepiride is a significantly cost-effective therapy when used as an initial combination therapy in patients of T2DM in lowering HbA1c and FPG."

Clinical • HEOR • Journal